Rok Cerne

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2016325/publications.pdf Version: 2024-02-01



POR CEDNE

#	Article	IF	CITATIONS
1	GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors. , 2022, 234, 108035.		48
2	Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABA _A) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy. Journal of Medicinal Chemistry, 2016, 59, 10800-10806.	6.4	43
3	The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders. Pharmacology Biochemistry and Behavior, 2022, 213, 173321.	2.9	27
4	The Positive Allosteric Modulator of <i>α</i> 2/3-Containing GABA _A Receptors, KRM-II-81, Is Active in Pharmaco-Resistant Models of Epilepsy and Reduces Hyperexcitability after Traumatic Brain Injury. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 83-94.	2.5	18
5	Imidazodiazepine Anticonvulsant, KRM-II-81, Produces Novel, Non-diazepam-like Antiseizure Effects. ACS Chemical Neuroscience, 2020, 11, 2624-2637.	3.5	10
6	The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81. Brain Research, 2019, 1722, 146356.	2.2	7
7	N-Substituted-3-alkoxy-derivatives of dextromethorphan are functional NMDA receptor antagonists in vivo: Evidence from an NMDA-induced seizure model in rats. Pharmacology Biochemistry and Behavior, 2021, 203, 173154.	2.9	4
8	Metabolism, pharmacokinetics, and anticonvulsant activity ofÂa deuterated analog of the α2/3â€selective GABAkine KRMâ€llâ€81. Biopharmaceutics and Drug Disposition, 2022, 43, 66-75.	1.9	4
9	Can GABAkines quiet the noise? The GABAA receptor neurobiology and pharmacology of tinnitus. Biochemical Pharmacology, 2022, 201, 115067.	4.4	3